


Blood will be collected for ctDNA test for the translational research program (see chapter 9) at: either within 3 days before start of treatment (elacestrant arm) or within 3 days after randomisation (standard endocrine treatment arm), week 4, and week 16 after randomisation and every 16 weeks thereafter for a maximum of 3 years (36 months or 156 weeks).



\* Stratification factors: duration of ET at the time of ctDNA detection (≤5 vs >5 years); stage (II vs III); prior CDK4/6 inhibitors; prior (neo)adjuvant chemotherapy; country; ctDNA test (Signatera vs others)  
 \*\* Depending on the duration of ET at the time of randomization: if 1-5 years, duration of 2-6 years to allow for 7 years of ET at the end of the study drug; if 5-7.5 years, duration of 2 years.  
 \*\*\* Same endocrine therapy as received during the screening phase

Figure 3: Study scheme




Figure 4: Maximum study treatment duration is dependent on the time patients are on ET (endocrine therapy) at the time of randomisation.